Oncology

#Drug discovery #ELRIG #Events #Oncology

Gaining a career in drug discovery: Tips and tricks from the inside 

Sygnature Discovery will be presenting a workshop at ELRIG UK’s Drug Discovery 2021 event entitled, Gaining a career in industry: Learning tips and tricks from the inside. It will take place on the first day of Drug Discovery 2021 in Liverpool, from 10.50 – 11.50am in Room 11B. … Read More

#News

#Biosciences #Cancer research #Immuno-oncology #Oncology

Platform to improve predictability of immuno-oncology drugs 

Crown Bioscience has launched its ‘3D Ex Vivo Patient Tissue Platform’ which, using freshly collected patient tumour material, can accurately measure oncology and immuno-oncology drug-induced tumour killing and endogenous immune cell proliferation in a high throughput format.   Researchers presented data on the new platform at 2021’s AACR-NCI-EORTC International Conference on Molecular Targets and… Read More

#News

#Cancer research #Oncology #Research #Small molecules

Novel therapy could be effective against paediatric leukaemia

Mount Sinai researchers have developed a therapy that shows promise against a fatal paediatric leukaemia. The small-molecule therapy was highly effective in fighting a type of acute myeloid leukaemia in both in vitro and in vivo experiments, according to research published in Science Translational Medicine in September 2021. The therapy, named MS67, causes… Read More

#News

#Blood cancer #Cancer research #Collaboration #Oncology

New cancer ‘inhibitor’ could lead to improved treatment options

Researchers have discovered a potential advancement in the treatment of chronic myeloid leukaemia (CML), which they hope will one day offer an improved option for treating patients with this form of blood cancer. The study– published in Science Translational Medicine and led by the University of Glasgow in collaboration with… Read More

#Cancer Research #Editor's Choice #News #Trending News

#Multi-omics #Oncology #Precision medicine #Single-cell analysis

Single-cell Sequencing 101: DNA & multi-omics for precision medicine

Cancer is a complex disease that continuously evolves in response to environmental pressures. The dynamism and heterogeneity of tumours have significant clinical implications. In this eBook, Mission Bio reviews how single-cell DNA sequencing and multi-omics are used to dissect clonal architecture, providing valuable insights for clinical strategies, therapeutic resistance, disease… Read More

#News

#Cancer #Clinical trials #Novel therapeutics #Oncology

CPRIT grant awarded to test potential large-molecule cancer drugs  

Qingyun Liu, leader of a preclinical development core where researchers can test the effectiveness of large molecule drug candidates for novel cancer treatments, has been awarded an approximately $4 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).  Liu is Professor of Precision Biomedicine with… Read More

#Cancer Research #News

#Biosciences #CRO #Drug development #Immuno-oncology #Oncology

High demand for preclinical expertise fuels growth for Nottingham CRO 

Nottingham, UK-based contract research organisation (CRO) Cellomatics Biosciences has reported year-on-year organic revenue growth of 30% since its inception in 2015, as demand for its preclinical and early discovery phase laboratory services and expertise continues to increase.   Based at BioCity Nottingham, Cellomatics is a specialist preclinical CRO with expertise in five main therapeutic areas: oncology,… Read More

#News

Covid-19
#Clinical trials #Covid-19 #Drug development #Oncology #Therapeutics

Oncology treatment tested in patients with moderate Covid-19 disease 

Australian clinical-stage drug development company Noxopharm has released preliminary top-line data from its NOXCOVID Phase I clinical trial testing the suitability of idronoxil (Veyonda), a TBK1 (TANK-binding kinase 1) inhibitor, as an anti-inflammatory in patients with moderate Covid-19 disease. Veyonda currently has two main drug actions – a moderating… Read More

#Covid-19 #News #Trending News

#Drug development #Oncology #Therapeutics

Avacta appoints Chief Scientific Officer of therapeutics division

Avacta has appointed Dr Fiona McLaughlin as Chief Scientific Officer of its therapeutics division, effective immediately. Dr McLaughlin is an experienced oncology drug developer, bringing over 25 years’ experience in research and translational drug development in the pharmaceutical and biotech sectors, having led teams from early research through to clinical… Read More

#Business & Investment #News

#AI #Drug development #Immuno-oncology #Machine learning #Oncology

Bristol Myers Squibb develops Exscientia’s drug candidate 

Exscientia has announced that Bristol Myers Squibb has elected to in-license its immune-modulating drug candidate. Exscientia has two active collaborations with Bristol Myers Squibb, which together focus on multiple therapeutic areas, including oncology and immunology. A significant expansion of the relationship was announced earlier this year.  The in-licensed candidate targets… Read More

#Cancer Research #News

#Covid-19 #Immunology / Virology & Vaccines #Moderna #Oncology

Moderna’s Covid-19 vaccine maintains antibodies against variants 

New data has been published on the durability of the Moderna Covid-19 vaccine in generating neutralising antibodies against variants. The manuscript was published in Science.   “We are pleased with these new data showing that people vaccinated with two doses of the Moderna Covid-19 vaccine maintained antibodies through six months, including against variants… Read More

#Covid-19 #News

#CAR-T #Cell therapy #GlobalData #Oncology #Tumour biology

Off-the-shelf potential for NK cell therapies for tumour treatment 

Natural killer (NK) cell therapies have the potential to be an effective, off-the-shelf treatment for a range of cancers. Analysis of NK cell therapies, currently in development, reveals that 57% of these are allogeneic therapies, and although development in haematological indications is more advanced, there are a high number of therapies… Read More

#Cancer Research #News

#Oncology #Therapeutics

Avacta appoints biotech executive and oncologist to bolster strategy

Avacta has appointed Dr Mark Goldberg as Non-executive Director to the Board with immediate effect. Dr Alastair Smith, Chief Executive Officer of Avacta, said Goldberg’s experience as a biotech executive and oncologist will greatly benefit the strategy and vision for the therapeutic business.  Dr Goldberg is a medical oncologist and haematologist on the faculty… Read More

#Business & Investment #News

#Immuno-oncology #Oncology #Pharma #Tumour biology

BridgeBio collaborates with Bristol Myers Squibb

BridgeBio Pharma has entered a clinical collaboration with Bristol Myers Squibb to evaluate the combination of BBP-398, a potentially best-in-class SHP2 inhibitor, with OPDIVO (nivolumab) in patients with advanced solid tumours with KRAS mutations with the hope of providing an effective new treatment option for patients with difficult-to-treat cancers.  The… Read More

#Cancer Research #News

#Cancer research #Clinical trials #Immuno-oncology #Oncology

Belarus adds hormone-resistant prostate and breast cancers to study  

The Republic of Belarus Ministry of Health has approved expanding the ongoing clinical trial of CureLab Oncology’s Elenagen, an experimental DNA therapy, to include hormone-resistant breast cancer and hormone-resistant metastatic prostate cancer.  The decision to add two more deadly diseases to the ongoing study was based on encouraging preliminary results… Read More

#Cancer Research #News